The therapeutic implications of these findings are demonstrated by the observations that OXPHOS inhibition decreases MYC levels and significantly suppresses the growth and self-renewal capacity of various well-characterized G3 MB cell lines, and other MYC-amplified cancer cells from multiple tumor types, including ovarian, colorectal and breast carcinomas. The gene discussed is MYC; the disease is breast carcinoma.